A Phase 2 interventional study of 80 mg RPH-104 and Placebo in Schnitzler Syndrome and Urticarial Vasculitis With Monoclonal Immunoglobulin M Component, Schnitzler (Disorder), sponsored by R-Pharm Overseas, Inc.. Withdrawn at 4 sites in United States. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2024-11-15.
Sponsored by R-Pharm Overseas, Inc. (part of R-Pharm) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 39 studies in Paraproteinemias with a site in United States — 6 open to participants now, 12 under way, 2 of them phase 3. Paraproteinemias · United States.
Among the 39 studies in Paraproteinemias with a site in United States, this one is the 31st largest by enrollment of the 32 interventional ones that give a count, is one of 2 that started in 2023, is one of 11 in phase 2, and was the 32nd registered.
69 studies on the registry are indexed under Paraproteinemias; 22 are open to participants now.
Browse Paraproteinemias studies →6 of the 39 studies in Paraproteinemias with a site in United States are open now. Recruiting first, the newest first:
Wake Forest University Health Sciences · Sites in United States
Ages 40–49 · Healthy volunteers
Kelonia Therapeutics, Inc. · Sites in United States, Australia
Ages 18+
OriCell Therapeutics Co., Ltd. · Sites in United States
Ages 18–75
Indiana University · Sites in United States
Ages 18+
University of Nebraska · Sites in United States
Ages 19–110 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 13 Paraproteinemias studies recruiting now, 7 (54%) set no upper age limit and 3 (23%) stop at 75 or younger; 1 takes children under 18; 3 take healthy volunteers.
This study: 18 Years to 100 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
39 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 17 · Phase 3 4
First in 1990; this study’s year is marked. 2 started in 2023.
By drug class, each counting the studies that test any of its medicines:
Median enrollment 47 across the 32 interventional studies, 300 across the 7 observational. Of the 23 that completed or were terminated, 10 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 39 have an industry lead sponsor. The 10 most frequent:
This study is registered under R-Pharm Overseas, Inc., one of the names counted as R-Pharm. Under that name alone:
R-Pharm Overseas, Inc. is the lead sponsor of 3 studies on the registry; none are open to participants now.
R-Pharm has 1 study filed under Paraproteinemias — fewer than ten, so there is no comparison to draw.
5 of the studies in Paraproteinemias with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06271252OriCell Therapeutics Co., Ltd.A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study | 2026-12-12 |
| NCT02671448Memorial Sloan Kettering Cancer CenterPilot Trial of Homebound Stem Cell Transplantation | 2027-01 |
| NCT07075185Kelonia Therapeutics, Inc.A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma | 2027-03 |
| NCT06870760Wake Forest University Health SciencesPre-malignant States to Hematologic Malignancies in Firefighters | 2027-04 |
| NCT03162536ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001) | 2027-09-17 |
Add all 5 to your calendar (.ics) → With an account.
Among the 39 studies in Paraproteinemias with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary goal of the study is to assess the efficacy and safety of RPH-104 in subjects with Schnitzler Syndrome using Schnitzler Disease Activity Score (SDAS), which includes the Physician's Global Assessment (PGA) and the local laboratory C-reactive protein (CRP) result
The study will include a screening period (up to 28 days), a double blind, placebo controlled treatment period (14 days), followed by an 8 week safety follow up period after the second dose of study drug.
Subjects with an established diagnosis of Schnitzler Syndrome (SchS) will participate in a Screening period of up to 28 days after signing an informed consent form (ICF). Subjects will be advised to schedule the Day 0 visit with the study staff as soon as the symptoms of SchS flare occur during the Screening period.
If the subject does not meet the inclusion/exclusion criteria at the site visit during the screening period, other screening visits are allowed within this period until the subject meets the study criteria.
A total of 14 subjects will be randomly assigned to 1 of 2 treatment groups (in a 1:1 ratio) to receive a double blind, single subcutaneous (SC) injection of study drug (80 mg RPH-104 or matching placebo) on Day 0. On Day 14, subjects will receive a second dose of randomized treatment as well as an additional dose of 80 mg RPH-104 or placebo based on response to treatment, such that responders (SDAS = 0) will receive a dose of placebo, and non responders defined as no response (no change in SDAS) or partial responders (SDAS ≥ 1, and activity reduction by 1 or more points of SDAS compared to baseline) will receive an 80 mg RPH 104 dose. (Schnitzler Disease Activity Score includes the PGA score and C-reactive protein (CRP) result: If the PGA and CRP grades are not of the same severity, the higher severity level of either PGA or CRP will be used to determine the SDAS)
The study will be stopped after Data and Safety Monitoring Board (DSMB) review if:
The severity of SchS symptoms will be assessed daily from Day 0 through Day 28 using the PR SchS Scale, at clinic visits on Day 0, Day 14, and Day 28 using the Patient Global Impression of Severity (PGIS), at clinic visits on Day 14 and Day 28 using the Patient Global Impression of Change (PGIC), and at each clinic visit using the PGA, CRP, SAA, and SDAS. Subjects will be followed through Day 70 for safety (A Data Safety Monitoring Board (DSMB) will periodically review and evaluate the accumulated study data for subject safety).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Confirmed diagnosis of SchS based on diagnostic criteria adapted by Lipsker as an urticarial skin rash (chronic), monoclonal IgM component (ie, IgM \< 10 g/L), or IgG (variant type), and at least of 2 of the following:
Highly effective contraceptive method is defined as follows:
i. Oral, injectable, or implanted hormonal contraceptives; in case of oral contraceptives the female subjects should administer the same product for at least 3 months prior to the study therapy.
ii. Intrauterine device or contraceptive system.
iii. Barrier methods: condom or occlusive cap (diaphragm or cervical cap/vaginal fornix cap) with spermicidal foam/gel/film/cream/vaginal suppository.
Exclusion Criteria:
7.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subject randomized to receive subcutaneous single injection of placebo on Day 0,and then, on Day 14 - second dose of randomized treatment + based on the positive response to treatment (SDAS = 0) one more dose of placebo
Drug: Placebo
Subject randomized to receive subcutaneous single injection of placebo on Day 0,and then, on Day 14 - second dose of randomized treatment + based on the lack of response (no change in SDAS) or partial response to treatment (SDAS ≥ 1, and activity reduction by 1 or more points of SDAS compared to baseline) subcutaneous single injection of 80 mg RPH-104
Biological: 80 mg RPH-104 · Drug: Placebo
Subject randomized to receive subcutaneous single injection of 80 mg RPH-104 on Day 0,and then, on Day 14 - second dose of randomized treatment + based on the positive response to the treatment (SDAS = 0) one subcutaneous injection of placebo
Biological: 80 mg RPH-104 · Drug: Placebo
Subject randomized to receive subcutaneous single injection of 80 mg RPH-104 on Day 0,and then, on Day 14 - second dose of randomized treatment + based on the lack of response (no change in SDAS) or partial response to treatment (SDAS ≥ 1, and activity reduction by 1 or more points of SDAS compared to baseline) one more subcutaneous injection of 80 mg RPH-104
Biological: 80 mg RPH-104
solution for subcutaneous administration 40 mg/mL, 2 mL in the 4-mL glass vial
Normal Saline (0.9% Sodium Chloride solution for Injection), 2 mL in the 4 mL-glass vial
Proportion of subjects with complete response (Schnitzler Disease Activity Score (SDAS = 0)) to therapy on Day 14 in the RPH-104 group as compared to the placebo group
• Proportion of subjects with complete response (SDAS = 0) to therapy on Day 14 in the RPH 104 treated group as compared to the placebo group based on SDAS using the PGA and the local laboratory CRP result
Time frame: Day 14
Change from baseline to Day 14 in subject-reported symptom severity of SchS: Patient-reported Severity of Schnitzler Syndrome Scale (PR-SchS Scale)
Change from baseline to Day 14 in subject-reported symptom severity of SchS using the Patient-reported Severity of Schnitzler Syndrome Scale (PR-SchS Scale). The PR-SchS Scale includes 5 features that are the most common and important SchS symptoms. These include rash, fever, tiredness, joint pain, and bone/muscle pain.
Time frame: Baseline and Day 14
Proportion of subjects with normalized serum amyloid A (SAA) and C-reactive protein (CRP) at Days 14 and 28
Proportion of subjects with normalized SAA (\< 10 mg/L) and CRP (≤ 10 mg/L) at Days 14 and 28
Time frame: Day 14 and Day 28
Change from baseline to Day 14 and Day 28 in CRP and SAA
Change from baseline to Day 14 and Day 28 in C-reactive protein and serum amyloid A
Time frame: Baseline, Day 28 and Day 14
Proportion of subjects with complete response (SDAS = 0) to therapy on Day 28 by treatment sequence based on SDAS using the Physician's Global Assessment (PGA) and the CRP result
Proportion of subjects with complete response (SDAS = 0) to therapy on Day 28 by treatment sequence (placebo - placebo, placebo - 80 mg RPH 104, 80 mg RPH 104 80 mg RPH 104, and 80 mg RPH 104 - 160 mg RPH 104) based on SDAS using the PGA and the CRP result.
Time frame: Baseline and Day 28
Proportion of subjects with partial response by treatment sequence on Days 14 and 28
Proportion of subjects with partial response (SDAS ≥ 1, and activity reduction by 1 or more points of SDAS compared to baseline) by treatment sequence (placebo - placebo, placebo 80 mg RPH 104, 80 mg RPH 104 80 mg RPH 104, and 80 mg RPH 104 160 mg RPH 104) on Days 14 and 28
Time frame: Baseline, Day 14 and Day 28
Change from baseline to Day 28 in subject reported symptom severity of SchS using the PR SchS Scale
Change from baseline to Day 28 in subject reported symptom severity of SchS using the PR SchS Scale
Time frame: Baseline, Day 14 and Day 28
Change from baseline to Day 14 and Day 28 in the Short Form-36 Version 2 Health Survey®
Change from baseline to Day 14 and Day 28 in the Short Form-36 Version 2 Health Survey® (SF 36v2 scale scores).It should be completed by the subject to assess of their quality of life over the preceding week.The SF 36v2 is a 36 item, patient reported survey of patient health. It consists of 8 health domains, including: Vitality,Physical functioning,Bodily pain, General health perceptions, Physical role functioning, Emotional role functioning, Social role functioning, Mental health.The SF 36v2 also produces 2 summary scores: the physical component summary (PCS) and mental component summary (MCS) scores
Time frame: Baseline, Day 14 and Day 28
Change from baseline to Day 14 and Day 28 in PGA total score
Change from baseline to Day 14 and Day 28 in PGA (Physician's Global Assessment) total score. 5 key symptoms of SchS (urticarial rash, fatigue, fever, myalgia, and arthralgia/bone pain) will be evaluated with a PGA score. Each symptom to be graded on a 4-point Likert scale where 0 = no, 1 = mild, 2 = moderate, and 3 = severe disease activity. The total PGA score to be ranged between 0 and 15.
Time frame: Baseline, Day 14 and Day 28
Change from baseline to Day 14 and Day 28 in PGIS scores
Change from baseline to Day 14 and Day 28 in PGIS scores (Patient Global Impression of Severity score: The PGIS asks subjects to describe the severity of their symptoms right now.Subjects are asked: "Please choose the response below that best describes the severity of your Schnitzler Syndrome symptoms today". Subjects rate their symptoms on a 5-point scale as "None", "Mild", "Moderate", "Severe", or "Very Severe")
Time frame: Baseline, Day 14 and Day 28
Proportion of subjects who are "Much Better" or "A Little Better" in PGIC scores at Day 14 and Day 28
Proportion of subjects who are "Much Better" or "A Little Better" in PGIC scores at Day 14 and Day 28. (PGIC is a 5-point scale, where the subjects should rate the overall change in their symptoms by comparing the severity of their symptoms right now with the severity of their symptoms before they began study treatment. Subjects are asked: "Please choose the response below that best describes the overall change in your Schnitzler Syndrome symptoms since you started taking the study medication". Subjects report their change in symptoms as "Much better","A Little Better", "No Change", "A Little Worse", or "Much worse")
Time frame: Day 14 and Day 28
Change from baseline to Day 14 and Day 28 in IgG levels
Change from baseline to Day 14 and Day 28 in immunoglobulin G (IgG) levels
Time frame: Baseline, Day 14 and Day 28
Change from baseline to Day 14 and Day 28 in IgM levels
Change from baseline to Day 14 and Day 28 in immunoglobulin M (IgM) levels
Time frame: Baseline, Day 14 and Day 28
Change from baseline to Day 14 and Day 28 in IgA levels
Change from baseline to Day 14 and Day 28 in Immunoglobulin A (IgA) levels
Time frame: Baseline, Day 14 and Day 28
Change from baseline to Day 14 and Day 28 in Kappa protein levels
Change from baseline to Day 14 and Day 28 in Kappa protein levels
Time frame: Baseline, Day 14 and Day 28
Change from baseline to Day 14 and Day 28 in Lambda protein levels
Change from baseline to Day 14 and Day 28 in Lambda protein levels
Time frame: Baseline, Day 14 and Day 28
Change from baseline to Day 14 and Day 28 in Paraprotein levels
Change from baseline to Day 14 and Day 28 in Paraprotein levels
Time frame: Baseline, Day 14 and Day 28
Change from baseline to Day 14 and Day 28 in Binding and neutralizing antidrug antibodies levels
Change from baseline to Day 14 and Day 28 in Binding and neutralizing antidrug antibodies levels
Time frame: Baseline, Day 14 and Day 28
Estimated half-life (t½) of RPH 104
Estimated t½ of RPH 104
Time frame: Baseline, Day 14, Day 28, Day 42, Day 70
Change from baseline to Day 14 and Day 28 in IL-1β, IL-1α, IL-1RA, and IL-6 levels
Change from baseline to Day 14 and Day 28 in IL-1β, IL-1α, IL-1 receptor antagonist (IL-1RA), and IL-6 levels
Time frame: Baseline, Day 14 and Day 28
Viral testing at Screening
Hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV) presence will be assessed
Time frame: Screening
QuantiFERON Gold Plus (TB) test at Screening
evidence of no active or latent M. tuberculosis infection as defined by local guidelines/local medical practice
Time frame: Screening
Pregnancy test for all WOCBP (women of childbearing potential)
serum chorionic gonadotropin test will be performed at screening and urine tests will be done at Baseline, Day 14, Day 28, Day 42, and Day 70
Time frame: Screening, Baseline, Day 14, Day 28, Day 42, and Day 70
Change in CRP (C-reactive protein) test results from screening to Day 28
CRP will be performed at both a local laboratory and the central laboratory. The local laboratory CRP test is to be processed on the same day the clinical assessments occur. Dosing cannot occur until these results are available on Day 0 and Day 14 to ensure eligibility and response to treatment.
Time frame: Screening, Baseline, Day 14, Day 28
Change in monoclonal proteins levels from baseline to Day 70
IgG, IgM, IgA, kappa, lambda, and paraprotein levels will be assessed
Time frame: Baseline, Day 14, Day 28, Day 42, and Day 70
Change in SAA (serum amyloid A) test results from Screening to Day 70
Serum levels of SAA have been found to be elevated in SchS, and systemic AA amyloidosis as a consequence of chronic inflammation has been reported in SchS.The SAA analysis will be performed at the central laboratory
Time frame: Screening, Baseline, Day 14, Day 28, Day 42, and Day 70
Start is estimated for May 2023; primary completion for Aug 2023, 3 months later.
How these figures are worked out, and which studies are left out of them.
This study is withdrawn, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Goflikicept